|
Volumn 13, Issue 4, 2009, Pages 356-357
|
Interest of the new criteria for drug trials in AD
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AMYLOID PROTEIN;
NOOTROPIC AGENT;
TAU PROTEIN;
ALZHEIMER DISEASE;
ARTICLE;
CEREBROSPINAL FLUID ANALYSIS;
COGNITIVE DEFECT;
DEMENTIA;
DISEASE COURSE;
DISEASE SEVERITY;
EARLY INTERVENTION;
HUMAN;
MILD COGNITIVE IMPAIRMENT;
NEUROIMAGING;
NEUROPATHOLOGY;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PATHOGENESIS;
POSITRON EMISSION TOMOGRAPHY;
PRIORITY JOURNAL;
RISK FACTOR;
VERBAL MEMORY;
ALZHEIMER DISEASE;
BIOLOGICAL MARKERS;
CLINICAL TRIALS AS TOPIC;
HUMANS;
RESEARCH DESIGN;
|
EID: 65249157896
PISSN: 12797707
EISSN: None
Source Type: Journal
DOI: 10.1007/s12603-009-0042-9 Document Type: Article |
Times cited : (8)
|
References (8)
|